Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 17Carcinoma, Hepatocellular 8Nasopharyngeal Carcinoma 7Recurrence 6Neoplasms 6Esophageal Neoplasms 6Breast Neoplasms 6Stomach Neoplasms 5Neoplasm Metastasis 5Esophageal Squamous Cell Carcinoma 5Colorectal Neoplasms 5Locally Advanced Rectal Cancer 4Carcinoma, Renal Cell 4Urinary Bladder Neoplasms 3Small Cell Lung Carcinoma 3Sarcoma 3Rectal Neoplasms 3Melanoma 3Head and Neck Neoplasms 3Colonic Neoplasms 3Cholangiocarcinoma 3Uterine Cervical Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Solid Tumors 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, B-Cell 2Leukemia, Myeloid, Acute 2Hyperthermia 2Chondrosarcoma 2Carcinoma, Transitional Cell 2

Interventions

sintilimab 2pembrolizumab 2Bevacizumab 2vicriviroc 1spartalizumab 1relatlimab 1dabrafenib 1atezolizumab 1Tiragolumab 1Nivolumab 1Immune Checkpoint Inhibitors 1Cetuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Spinocerebellar Degenerations × Immune Checkpoint Inhibitors × Clear all
NCT06835179 2025-02-19

SBRT Combined With CAPEOX, Bevacizumab, and PD-1 Inhibitor for the Treatment of RAS-Mutant, MSS-Type, Unresectable Metastatic Colorectal Cancer.

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Not yet recruiting
28 enrolled
Gastrointestinal

Spinocerebellar Degenerations, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡